
## John C Ford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9108371/publications.pdf Version: 2024-02-01



IOHN C FORD

#	Article	IF	CITATIONS
1	Prostate cancer radiomics and the promise of radiogenomics. Translational Cancer Research, 2016, 5, 432-447.	1.0	111
2	Quantitative Radiomics: Impact of Pulse Sequence Parameter Selection on MRI-Based Textural Features of the Brain. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	79
3	Predictive value of 0.35ÂT magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. Medical Physics, 2020, 47, 3682-3690.	3.0	35
4	Impact of contouring variability on oncological PET radiomics features in the lung. Scientific Reports, 2020, 10, 369.	3.3	34
5	Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study. Lung Cancer, 2016, 96, 113-119.	2.0	32
6	MR-Guided Radiotherapy for Brain and Spine Tumors. Frontiers in Oncology, 2021, 11, 626100.	2.8	27
7	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. Translational Andrology and Urology, 2018, 7, 445-458.	1.4	26
8	The role of radiomics in prostate cancer radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 900-912.	2.0	24
9	Classification of suspicious lesions on prostate multiparametric MRI using machine learning. Journal of Medical Imaging, 2018, 5, 1.	1.5	24
10	Variabilities of Magnetic Resonance Imaging–, Computed Tomography–, and Positron Emission Tomography–Computed Tomography–Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2017, 99, 80-89.	0.8	21
11	Daily Tracking of Glioblastoma Resection Cavity, Cerebral Edema, and Tumor Volume with MRI-Guided Radiation Therapy. Cureus, 2018, 10, e2346.	0.5	21
12	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. Medical Physics, 2021, 48, 2386-2399.	3.0	13
13	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. Physica Medica, 2020, 77, 154-159.	0.7	11
14	MRI-guided stereotactic ablative radiation therapy of spinal bone metastases: a preliminary experience. British Journal of Radiology, 2020, 93, 20190655.	2.2	9
15	Automatic Detection of Prostate Tumor Habitats using Diffusion MRI. Scientific Reports, 2018, 8, 16801.	3.3	8
16	Impact of quantization algorithm and number of gray level intensities on variability and repeatability of low field strength magnetic resonance image-based radiomics texture features. Physica Medica, 2020, 80, 209-220.	0.7	8
17	Magnetic Resonance-guided External Beam Radiation and Brachytherapy for a Patient with Intact Cervical Cancer. Cureus, 2018, 10, e2577.	0.5	8
18	Assessment of CT to CBCT contour mapping for radiomic feature analysis in prostate cancer. Scientific Reports, 2021, 11, 22737.	3.3	7

John C Ford

#	Article	IF	CITATIONS
19	Predictive Value of Delta-Radiomics Texture Features in 0.35 Tesla Magnetic Resonance Setup Images Acquired During Stereotactic Ablative Radiotherapy of Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 807725.	2.8	4
20	SU-F-R-57: Validation of Quantitative Radiomic Texture Features for Oncologic MRI: A Simulation Study. Medical Physics, 2016, 43, 3386-3386.	3.0	2
21	SU-F-R-35: Repeatability of Texture Features in T1- and T2-Weighted MR Images. Medical Physics, 2016, 43, 3380-3381.	3.0	1
22	Analysis of Magnetic Resonance Image Signal Fluctuations Acquired During MR-Guided Radiotherapy. Cureus, 2018, 10, e2385.	0.5	1
23	SU-F-J-84: Comparison of Quantitative Deformable Image Registration Evaluation Tools: Application to Prostate IGART. Medical Physics, 2016, 43, 3425-3426.	3.0	1
24	NIMG-56. USING RADIOMIC FEATURES FROM DAILY MAGNETIC RESONANCE IMAGING TO PREDICT RESPONSE TO RADIATION THERAPY IN GLIOBLASTOMA PATIENTS: A PILOT STUDY. Neuro-Oncology, 2021, 23, vi142-vi142.	1.2	0